Author/Authors :
Mandelbaum، نويسنده , , Jonathan and Bhagat، نويسنده , , Govind and Tang، نويسنده , , Hongyan and Mo، نويسنده , , Tongwei and Brahmachary، نويسنده , , Manisha and Shen، نويسنده , , Qiong and Chadburn، نويسنده , , Amy and Rajewsky، نويسنده , , Klaus and Tarakhovsky، نويسنده , , Alexander and Pasqualucci، نويسنده , , Laura and Dalla-Favera، نويسنده , , Riccardo، نويسنده ,
Abstract :
Summary
e large B cell lymphoma (DLBCL) is a heterogeneous disease composed of at least two distinct subtypes: germinal center B cell-like (GCB) and activated B cell-like (ABC) DLBCL. These phenotypic subtypes segregate with largely unique genetic lesions, suggesting the involvement of different pathogenetic mechanisms. In this report we show that the BLIMP1/PRDM1 gene is inactivated by multiple mechanisms, including homozygous deletions, truncating or missense mutations, and transcriptional repression by constitutively active BCL6, in ∼53% of ABC-DLBCL. In vivo, conditional deletion of Blimp1 in mouse B cells promotes the development of lymphoproliferative disorders recapitulating critical features of the human ABC-DLBCL. These results demonstrate that BLIMP1 is a bona fide tumor-suppressor gene whose loss contributes to lymphomagenesis by blocking plasma cell differentiation.